20 results about "Lipid binding" patented technology

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

Methods of using lipid binding protein molecules to treat a subject having or at risk of one or more conditions, such as sepsis (e.g., septic shock).

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

The invention relates to a vaccine platform, comprising a lipid binding amino acid sequence and an oligomerization sequence. In particular, the lipid binding amino acid sequence and an oligomerization sequence are derived from filensin, a protein with no or minimal immunogenicity. Filensin has an extremely strong membrane binding capacity and oligomerization property, making it an ideal carrier for an antigenic moiety. An immunization platform comprising a nucleic acid sequence(s) coding for a lipid binding amino acid sequence and an oligomerization sequence is also provided.

[Problem] To provide, inter alia, an information processing system with which it is possible to accurately estimate binding force to lipid [Solution] According to one aspect of the present invention, provided is an information processing system comprising a processor configured to execute the next steps by reading a program. In an acquisition step, an amino acid sequence for which an inference is to be carried out is acquired. In an inference step, the binding force, to lipid, of a protein having the amino acid sequence for which an inference is to be carried out is inferred on the basis of the amino acid sequence for which an inference is to be carried out, and reference information. The reference information includes a correlation between the amino acid sequence and the binding force, the correlation being constructed on the basis of actually measured values of the binding force.

This invention relates to the fields of environmental and bioanalytical technology, and particularly to a method for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. The technical solution includes a framework process for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. This invention establishes a dual-solvent secondary extraction system composed of n-hexane and methyl tert-butyl ether, achieving differentiated adaptation to different tissue matrices. By combining the advantages of non-polar and moderately polar solvents, it can simultaneously handle the relatively highly polar bisphenol S and the relatively non-polar bisphenol AF in a single extraction process. Furthermore, this method sets key physical parameters during the extraction process according to the histological characteristics of each organ. For heart and lung tissues, specific ultrasonic power is used to ensure thorough cell disruption; while for liver and spleen with high lipid content, different power and time are used to ensure the full release of lipid-bound target substances.

Methods for treating acute conditions (e.g., acute conditions comprising acute inflammation), such as cytokine release syndrome, sepsis and acute kidney injury using lipid binding protein-based complexes.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

The present invention relates to monoclonal antibodies to the HCV core lipid binding domain. The present invention provides monoclonal antibodies for detecting Hepatitis C Virus (HCV) antigens. The antibodies specifically immunoreact with at least one epitope of the lipid binding domain of amino acid residues 134-171 of the HCV core antigen. Further provided are immunoassay methods for detecting HCV infection using the antibodies, kits comprising the antibodies, and compositions.

Methods of using a lipid binding protein molecule to treat a subject having one or more conditions or at risk of one or more conditions. The method generally includes measuring ApoA-I levels and / or HDL cholesterol levels in the subject, and administering one or more doses of the lipid binding protein molecule to the subject if the measured ApoA-I levels are below a target ApoA-I level or target ApoA-I range, and / or the measured HDL levels are below a target HDL level.

The invention discloses application of morusin O in preparation of a TEAD protein palmitoylation inhibitor, and relates to the technical field of molecular biology. The invention also provides a TEAD palmitoylation inhibitor and a method for screening the TEAD palmitoylation inhibitor in vitro. It is found for the first time that the compound can be directly combined with a lipid binding pocket of TEAD1 protein to interfere the post-translational palmitoylation modification level of the TEAD1 protein, so that the conformational stability and transcriptional activity of TEAD1 are reduced, and the application value is wide.

A lipid-binding protein comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, wherein the glycine residue at position 12 from the N-terminus of the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid residue selected from the group consisting of cysteine, valine, leucine, isoleucine, alanine, and methionine, and wherein the lipid-binding protein has a higher binding affinity for PI(3,5)P₂ than a protein consisting of the amino acid sequence of SEQ ID NO: 1.

This disclosure provides therapeutic nanodiscs comprising a lipid-binding polypeptide, a lipid bilayer, and a therapeutic agent, wherein the therapeutic agent may be used to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries. The lipid bilayer may be 1,2-dimiristoyl-sn-glycero-3-phosphocholine (DMPC), and the therapeutic agent may be a nucleic acid polymer. Furthermore, methods for administering therapeutic nanodiscs to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries, as well as the use of such therapeutic nanodiscs, are provided.

Methods for treating hyperinflammatory conditions such as hemophagocytic lymphohistiocytosis (HLH), dengue hemorrhagic fever, and dengue shock syndrome using lipid binding protein-based complexes.

A fusion protein formed by a conditionally-activated lipid-binding domain that exposes a lipid moiety in response to a stimulus that is fused to a stimulus-responsive polypeptide domain. An exemplary conditionally-activate domain, a prototypical myristoyl switch, was fused with a thermo-responsive coil-protein. Biophysical characterizations confirmed the integrity and functionality of recoverin's myristoyl-switch within the fusion protein. Dynamic light scattering and cryo-TEM demonstrated that liposwitching modulates temperature-triggered phase separation and the hierarchical assembly of the fusion proteins. The fusion protein can therefore respond emergently to biologically relevant signals in a manner that mirrors the adaptability of riboswitches

The invention belongs to the field of functional food and natural product chemistry, and particularly relates to a polygonatum sibiricum tea composition with a lipid regulating function and a preparation method of the polygonatum sibiricum tea composition. The composition is prepared from a modified rhizoma polygonati extract, 4-hydroxy-3-methoxyphenylpyruvic acid, green tea powder, lotus leaf powder, malt flour and a fructus momordicae extract. The modified polygonatum sibiricum extract is prepared by modifying a polygonatum sibiricum extracting solution through a gallic acid-L-serine deep eutectic system, an esterification and hydrogen bond recombination structure is formed in the modification process, and the hydrophobicity, the oxidation resistance and the lipid binding capacity of polygonatum sibiricum polysaccharide are remarkably improved. 4-hydroxy-3-methoxyphenylpyruvic acid is used as natural aromatic organic acid, and has a synergistic effect with the modified rhizoma polygonati extract, so that cholesterol excretion can be promoted, and lipid peroxidation can be inhibited. The composition disclosed by the invention has excellent performance in the aspects of reducing serum cholesterol and triglyceride, improving the free radical scavenging rate and maintaining the stability of the tea powder, is obviously superior to an unmodified or single modified system, and has structural innovation and a good application prospect.

A combination of a lipid-binding molecule and / or a lipid-binding protein and a lipid component (i.e., mispid) for modulating the interaction of a target molecule with a lipid membrane is provided. This includes, for example, the use of the lipid binding molecules and / or mispid to improve the sequencing efficiency and flux of nanopore-based sequencing systems. For sequencing a target molecule, such as a nucleic acid sequence or a substitute nucleic acid polymer derived therefrom, a lipid-binding molecule and / or a mispid thereof is combined with the target molecule. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of the lipid-binding molecules and / or nanodisks, thereby improving capture, time of arrival and effective concentration of the target molecules across the membrane of the chip. This improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

The present invention provides compounds used for the treatment of acute conditions including sepsis, sepsis-associated AKI, ischemia / reperfusion AKI, and CSA AKI, as well as CRS, such as CRS associated with immunotherapy and CRS secondary to infections like COVID-19. [Solution] A lipid-binding protein-based complex is provided for use in a method of treating an acute condition, the method comprising the step of administering a high dose of the lipid-binding protein-based complex to a subject in need thereof, the acute condition may include acute inflammation.